Blog Post
Deal in Review: AbbVie Acquires ImmunoGen
AbbVie has agreed to acquire cancer biotech ImmunoGen (IMGN) for $10.1 billion in an all cash offering for $31.26 per share. J.P Morgan and Morgan
AbbVie has agreed to acquire cancer biotech ImmunoGen (IMGN) for $10.1 billion in an all cash offering for $31.26 per share. J.P Morgan and Morgan